Stonepine Capital Management, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001440771
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2025 · 58 positions · Total reported value $96.28M · Top-10 concentration 59.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 72.7% · 16 new · 27 cut · 29 exited
Active Share (vs S&P 500): 99.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -2.9% · vs SPY -5.0% · Prev Value $151.28M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -4.9% · vs SPY -7.1% · Latest Value $130.24M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2025 13F filing, Stonepine Capital Management, LLC disclosed 58 equity positions with a combined reported value of $96.28M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 59.6% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2025 were ADMA ($13.66M), EOLS ($8.44M), ZVRA ($6.83M). By sector, the heaviest allocations are Health Care 84.8%, Information Technology 0.4%. Versus the prior quarter, allocation shifted toward Health Care (+3.9pp) and away from Other (-4.3pp).
Versus the prior quarter, Stonepine Capital Management, LLC opened 16 new positions, trimmed 27 and fully exited 29, a turnover rate of 72.7% of positions. The portfolio's overlap with the prior quarter was 44% of names.
The largest new positions opened in Q2 2025 were ARDX ($2.18M), NKTR ($1.30M), ALMS ($1.05M).
Of the 29 positions fully exited versus the prior quarter, the largest were OPTN ($7.23M), URGN ($3.69M), AQST ($3.04M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2025)
Fully Exited (vs previous quarter)
- OPTN OPTINOSE INC · prev qtr: $7.23M
- URGN UROGEN PHARMA LTD · prev qtr: $3.69M
- AQST AQUESTIVE THERAPEUTICS INC · prev qtr: $3.04M
- LKFT LAKEFRONT BIOTHERAPEUTICS NV · prev qtr: $2.36M
- EDSA EDESA BIOTECH INC · prev qtr: $1.68M · history
- KROS KEROS THERAPEUTICS INC · prev qtr: $1.02M
- SCPH SCPHARMACEUTICALS INC · prev qtr: $914.42K
- INO INOVIO PHARMACEUTICALS INC · prev qtr: $844.88K
Insider Transactions (Form 4)
Latest Stonepine Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Stonepine Capital Management, LLC is an SEC-registered 13F filer based in Bend, OR, United States. As of Q2 2026 it reported 83 US equity positions with a combined value of $151.28M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: BEND, OR, United States
- SEC registration: 801-136874 (status: Approved), registered 2026-07-22
- Regulatory AUM (Form ADV): $181.00M as of 2026-06-26
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: stonepinecap.com
Portfolio Structure
- 83 positions · $151.28M reported value (Q2 2026)
- Top 10 holdings = 44.6% of reported value
- Largest position: VSTM (VERASTEM INC) at 8.5%
- Average position size: $1.82M
Sector Tilt
- Health Care 99.8%
- Industrials 0.2%
- Materials 0.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 23 new, 28 added, 24 reduced, 12 exited
- 8 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
750.00K | $13.66M | 14.19% | Reduce | |
| 2 |
|
916.50K | $8.44M | 8.77% | Reduce | |
| 3 |
|
775.62K | $6.83M | 7.10% | Add | |
| 4 |
|
350.00K | $5.16M | 5.36% | Add | |
| 5 |
|
225.00K | $4.85M | 5.04% | Add | |
| 6 |
|
604.07K | $4.57M | 4.74% | Add | |
| 7 |
|
2.08M | $4.04M | 4.20% | Add | |
| 8 |
|
152.14K | $3.83M | 3.98% | Add | |
| 9 |
|
310.03K | $3.09M | 3.21% | Add | |
| 10 |
|
450.00K | $2.92M | 3.04% | Add | |
| 11 |
|
306.03K | $2.74M | 2.84% | Add | |
| 12 |
|
38.60K | $2.52M | 2.62% | Reduce | |
| 13 |
|
555.00K | $2.18M | 2.26% | New | |
| 14 |
|
190.59K | $2.02M | 2.09% | Reduce | |
| 15 |
|
812.68K | $1.77M | 1.84% | Add | |
| 16 |
|
733.79K | $1.43M | 1.49% | Reduce | |
| 17 |
|
1.00M | $1.41M | 1.46% | Add | |
| 18 |
|
657.38K | $1.36M | 1.41% | Reduce | |
| 19 |
|
50.20K | $1.30M | 1.35% | New | |
| 20 |
|
285.30K | $1.29M | 1.34% | Add | |
| 21 |
|
41.50K | $1.23M | 1.27% | Add | |
| 22 |
|
250.00K | $1.18M | 1.23% | Add | |
| 23 |
|
100.00K | $1.13M | 1.17% | Add | |
| 24 |
|
349.62K | $1.05M | 1.09% | New | |
| 25 |
|
457.42K | $988.02K | 1.03% | Add | |
| 26 |
|
219.00K | $976.74K | 1.01% | New | |
| 27 |
|
205.10K | $957.82K | 0.99% | Add | |
| 28 |
|
845.97K | $896.73K | 0.93% | Add | |
| 29 |
|
92.90K | $870.01K | 0.90% | New | |
| 30 |
|
292.50K | $868.73K | 0.90% | Reduce | |
| 31 |
|
169.86K | $777.95K | 0.81% | Add | |
| 32 |
|
77.14K | $765.24K | 0.80% | New | |
| 33 |
|
333.33K | $753.33K | 0.78% | New | |
| 34 |
|
491.30K | $697.65K | 0.72% | Reduce | |
| 35 |
|
130.00K | $655.20K | 0.68% | Reduce | |
| 36 |
|
151.09K | $623.98K | 0.65% | Add | |
| 37 |
|
50.00K | $623.00K | 0.65% | New | |
| 38 |
|
544.49K | $577.16K | 0.60% | New | |
| 39 |
|
178.00K | $512.64K | 0.53% | Reduce | |
| 40 |
|
156.89K | $454.98K | 0.47% | New | |
| 41 |
|
226.01K | $449.76K | 0.47% | Reduce | |
| 42 |
|
189.05K | $446.16K | 0.46% | Add | |
| 43 |
|
100.00K | $415.00K | 0.43% | Reduce | |
| 44 |
|
145.90K | $377.88K | 0.39% | New | |
| 45 |
|
100.00K | $377.00K | 0.39% | New | |
| 46 |
|
7.00K | $298.97K | 0.31% | Reduce | |
| 47 |
|
30.00K | $297.60K | 0.31% | New | |
| 48 |
|
45.00K | $255.60K | 0.27% | New | |
| 49 |
|
85.00K | $193.80K | 0.20% | Add | |
| 50 |
|
82.43K | $172.28K | 0.18% | New | |
FAQ
What did Stonepine Capital Management, LLC buy in 2025-Q2?
In its 2025-Q2 13F filing, Stonepine Capital Management, LLC reported 58 equity positions worth $96.28M in aggregate; its largest disclosed positions were ADMA ($13.66M), EOLS ($8.44M), ZVRA ($6.83M).
How large is Stonepine Capital Management, LLC's portfolio?
Stonepine Capital Management, LLC reported $96.28M of long equity holdings across 58 positions as of 2025-Q2. Top-10 holdings account for 59.6% of reported value.
What is Stonepine Capital Management, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.